Reduction of risk of death or MI in patients with previous infarction or unstable angina pectoris,
Recurrent transient ischemia attacks (TIAs) or stroke in men who have had transient brain ischemia caused by platelet emboli.
Prevention of cataract formation; prevention of toxemia of pregnancy; improvement of inadequate uteroplacental blood flow in pregnancy; prophylaxis against thromboembolic events in patients with atrial fibrillation, mitral valve prolapse, peripheral arterial disease, bioprosthetic or mechanical heart valves, and in pregnant patients with prosthetic heart valves; antithrombotic therapy in children with Blalock-Taussig shunt or ischemic stroke, and in children after Fontan surgery.
Inhibits prostaglandin synthesis, resulting in analgesia, anti-inflammatory activity, and platelet aggregation inhibition; reduces fever by acting on the brain’s heat-regulating center to promote vasodilation and sweating.
Absorption: Well absorbed from the upper small intestine; absorption from enteric-coated preparations may be unreliable; rectal absorption is slow and variable.
Distribution: Rapidly and widely distributed; crosses the placenta and enters breast milk.
Metabolism/Excretion: Extensively metabolized by the liver; inactive metabolites excreted by the kidneys. Amount excreted unchanged by the kidneys depends on urine pH; as pH increases, amount excreted unchanged increases from 2–3% up to 80%.
Half-life: 2–3 hr for low doses; up to 15–30 hr with larger doses because of saturation of liver metabolism.